Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 1, 2014

BioPharm International

  • BioPharm International-03-01-2014
  • Volume 27
  • Issue 3

Stain-Free Chromatography Workflow

Stain-Free Chromatography Workflow

Bio-Rad’s new stain-free chromatography workflow can save hours of any protein purification workflow with TGX Stain-Free gels and the NGC chromatography system, according to the company. With faster run times and the elimination of staining and destaining, TGX Stain-Free Gels provide quick checkpoints for purity and yield throughout the chromatography workflow. When used in combination with the NGC chromatography system, researchers can complete the entire protein purification process in less time.

With the NGC platform, professionals can automatically plumb and program their chromatography system. In addition, the platform accepts new components and routinely configures the system to work with these components, allowing researchers to address new applications and increase throughput as needed. By using TGX Stain-Free gels, researchers can cut the time it takes to run gels to analyze the chromatography fractions to approximately 25 minutes.

Bio-Rad


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.